Edition:
United States

Pain Therapeutics Inc (PTIE.O)

PTIE.O on Nasdaq

4.13USD
19 Sep 2017
Change (% chg)

-- (--)
Prev Close
$4.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,440
52-wk High
$21.00
52-wk Low
$3.10

Latest Key Developments (Source: Significant Developments)

Pain Therapeutics reports Q2 loss per share $0.64
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics reports Q2 2017 financial results and mid-year corporate update.Q2 loss per share $0.64.  Full Article

Pain Therapeutics announces FDA clears investigational new drug application for PTI-125
Monday, 31 Jul 2017 08:00am EDT 

July 31 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics announces FDA has cleared an investigational new drug (IND) application for PTI-125.Pain Therapeutics Inc - ‍company's phase I study with PTI-125 will be funded by a $1.7 million grant from NIH​.Pain Therapeutics Inc - ‍FDA cleared its investigational new drug (IND) application for PTI-125, a novel drug candidate to treat Alzheimer's disease​.Pain Therapeutics- ‍clinical testing with PTI-125 will begin shortly, with funding provided by a $1.7 million research grant from National Institutes of Health​.  Full Article

Pain Therapeutics announces reverse stock split
Monday, 8 May 2017 09:14am EDT 

May 8 (Reuters) - Pain Therapeutics Inc :Pain therapeutics announces reverse stock split.Pain therapeutics inc - that it will effect a 7-for-1 reverse split of its outstanding shares of common stock effective may 9, 2017.  Full Article

Pain Therapeutics reports Q1 loss per share $0.06
Tuesday, 25 Apr 2017 05:47pm EDT 

April 25 (Reuters) - Pain Therapeutics Inc -:Pain Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.06.  Full Article

Pain Therapeutics files for mixed shelf of up to $75 mln
Friday, 14 Apr 2017 06:25pm EDT 

Pain Therapeutics Inc :Files for mixed shelf of up to $75 million - sec filing.  Full Article

Pain Therapeutics announces resignation of Peter Roddy as CFO
Friday, 17 Feb 2017 09:02am EST 

Pain Therapeutics Inc :On Feb 14, 2017, Peter Roddy resigned, effective March 9, 2017, as vice president, chief financial officer.  Full Article

Pain Therapeutics reports qtrly loss per share $0.06
Friday, 17 Feb 2017 09:00am EST 

Pain Therapeutics Inc : Pain therapeutics reports 2016 financial results . Qtrly loss per share $0.06 .Pain Therapeutics - in first two quarters of 2017, company expects its quarterly net cash burn rate will range from $2.0 million to $2.5 million.  Full Article

Pain Therapeutics to discuss remoxy ER with FDA
Tuesday, 20 Dec 2016 09:00am EST 

Pain Therapeutics Inc: Pain therapeutics to discuss remoxy® ER with FDA . Plans to meet with FDA in person on Monday, February 13, 2017 to discuss regulatory path forward for remoxy ER . Pain therapeutics - during its upcoming meeting with FDA, company plans to open a scientific dialogue around intranasal (snorting) route of abuse . Company will provide details of this FDA meeting after receipt of final meeting minute .Pain therapeutics - company believes remoxy ER's thick, sticky, high-viscosity drug mass is a key feature of its abuse deterrent properties.  Full Article

Pain Therapeutics Q2 loss per share $0.07
Tuesday, 19 Jul 2016 04:30pm EDT 

Pain Therapeutics Inc : Pain Therapeutics reports Q2 2016 financial results .Q2 loss per share $0.07.  Full Article

Durect says PDUFA date for remoxy NDA of Sept 25 unchanged
Friday, 1 Jul 2016 09:05am EDT 

Durect Corp : Says prescription drug user fee act (PDUFA) date for remoxy NDA of September 25, 2016 is unchanged . An FDA advisory committee meeting for remoxy is not needed and no change to September 25, 2016 PDUFA date . Pain Therapeutics stated that FDA advised them that regulatory review of remoxy new drug application (NDA) remains active and on-going .Durect provides remoxy update.  Full Article

BRIEF-National Institute on Drug Abuse awards Pain Therapeutics $2.2 mln grant

* National Institute on Drug Abuse awards Pain Therapeutics $2.2 million grant Source text for Eikon: Further company coverage: